These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29019253)

  • 1. Immune mediated colitis caused by lung cancer treatment with atezolizumab.
    González Vázquez S; de la Riva Onandía S; Echeveste JI; Muñoz Navas M
    Rev Esp Enferm Dig; 2017 Dec; 109(12):863-864. PubMed ID: 29019253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
    Krishnamurthy A; Jimeno A
    Drugs Today (Barc); 2017 Apr; 53(4):217-237. PubMed ID: 28492290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Anti-PD-L1 Drug Approved for NSCLC.
    Cancer Discov; 2016 Dec; 6(12):OF1. PubMed ID: 27920140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
    Weinstock C; Khozin S; Suzman D; Zhang L; Tang S; Wahby S; Goldberg KB; Kim G; Pazdur R
    Clin Cancer Res; 2017 Aug; 23(16):4534-4539. PubMed ID: 28611199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis.
    Hsu PC; Li SH; Yang CT
    J Thorac Oncol; 2018 Nov; 13(11):e227-e230. PubMed ID: 30368415
    [No Abstract]   [Full Text] [Related]  

  • 10. The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
    Zhuo M; Chen H; Zhang T; Yang X; Zhong J; Wang Y; An T; Wu M; Wang Z; Huang J; Zhao J
    Cancer Biomark; 2018; 22(3):467-476. PubMed ID: 29758930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
    Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
    Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
    Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
    Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.
    Birnbaum MR; Ma MW; Casey MA; Amin BD; Jacobson M; Cheng H; McLellan BN
    J Drugs Dermatol; 2017 Oct; 16(10):1047-1049. PubMed ID: 29036261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
    Inman BA; Longo TA; Ramalingam S; Harrison MR
    Clin Cancer Res; 2017 Apr; 23(8):1886-1890. PubMed ID: 27903674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction: A case report
.
    Li J; Deng X; Wang B; Li W
    Int J Clin Pharmacol Ther; 2019 Dec; 57(12):607-611. PubMed ID: 31488241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
    Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
    Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].
    Jiang Z; Pan Z; Ren X
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):138-142. PubMed ID: 28228226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in lung cancer: past, present and future.
    Seetharamu N; Budman DR; Sullivan KM
    Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.